Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 1/2015

01.04.2015 | short review

Optimal follow-up of ovarian cancer patients

verfasst von: MD, PhD Eduard Vrdoljak, MD Branka Petrić Miše, MD, PhD Tihana Boraska Jelavić, MD, PhD Snježana Tomić, MD, PhD Dinka Šundov, MD Ante Strikić

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

Gynecological malignancies account for roughly 10 % of all cancers in women with ovarian cancer as leading cause of death due to gynecological tumors. Surveillance programs of ovarian cancer are primarily based on recurrence rates, timing of recurrence, salvage options, and chances for cure of patient with recurrence. Since there is no prospective, high evidence data on optimal surveillance program after primary treatment of patients with ovarian cancer recommendations are based on review of retrospective data sets. From all the diagnostic tools available, history taking and clinical examination, including gynecological examination, still contribute to the greatest number of recurrence detections. Radiologic and laboratory tests are usually employed when a suspicion of recurrence is raised. Follow-up plan should be tailored according to the estimated risk of relapse for individual patient.
Literatur
1.
Zurück zum Zitat Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://​globocan.​iarc.​fr. Accessed: 6 July 2014. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. http://​globocan.​iarc.​fr. Accessed: 6 July 2014.
2.
Zurück zum Zitat Salani R, Backes FJ, Fung Kee Fung M, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignances: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 2011;204(6):466–78. doi:10.1016/j.ajog.2011.03.008. CrossRefPubMed Salani R, Backes FJ, Fung Kee Fung M, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignances: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol. 2011;204(6):466–78. doi:10.1016/j.ajog.2011.03.008. CrossRefPubMed
3.
Zurück zum Zitat Gadducci A, Cosio S. Surveillance of patients after initial treatment of ovarian cancer. Crit Rev Oncol Hematol. 2009;71(1):43–52. doi:10.1016/jcritrevonc.2008.12.008. CrossRefPubMed Gadducci A, Cosio S. Surveillance of patients after initial treatment of ovarian cancer. Crit Rev Oncol Hematol. 2009;71(1):43–52. doi:10.1016/jcritrevonc.2008.12.008. CrossRefPubMed
5.
Zurück zum Zitat Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: resent advances. Hum Pathol. 2009;40(9):1213–23. doi:10.1016/j.humpath.2009.04.017. CrossRefPubMed Gilks CB, Prat J. Ovarian carcinoma pathology and genetics: resent advances. Hum Pathol. 2009;40(9):1213–23. doi:10.1016/j.humpath.2009.04.017. CrossRefPubMed
6.
Zurück zum Zitat Helleman J, van Staveren IL, Dinjens WN, et al. Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer. 2006;6:201. doi:10.1186/1471-2407-6-201. CrossRefPubMedCentralPubMed Helleman J, van Staveren IL, Dinjens WN, et al. Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer. 2006;6:201. doi:10.1186/1471-2407-6-201. CrossRefPubMedCentralPubMed
8.
Zurück zum Zitat Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2006;102(3):432–9. CrossRefPubMed Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol. 2006;102(3):432–9. CrossRefPubMed
9.
Zurück zum Zitat Armstrong DK, Bundy B, Wenzel L, et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43. CrossRefPubMed Armstrong DK, Bundy B, Wenzel L, et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34–43. CrossRefPubMed
10.
Zurück zum Zitat Trimbos JB, Parmar M, Vergote I, et al. International Collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trial of adjuvant chemotherapy in patients with early stage ovarian carcinoma. J Natl Cancer Inst. 2003;95(2);105–112. CrossRefPubMed Trimbos JB, Parmar M, Vergote I, et al. International Collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trial of adjuvant chemotherapy in patients with early stage ovarian carcinoma. J Natl Cancer Inst. 2003;95(2);105–112. CrossRefPubMed
11.
Zurück zum Zitat Gadducci A, Cosio A, Zola P, et al. The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicentre retrospective Italian study. Gynecol Oncol. 2010;116(3):358–63. doi:10.1016/j.ygyno.2009.11.008. CrossRefPubMed Gadducci A, Cosio A, Zola P, et al. The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicentre retrospective Italian study. Gynecol Oncol. 2010;116(3):358–63. doi:10.1016/j.ygyno.2009.11.008. CrossRefPubMed
12.
Zurück zum Zitat Chan JK, Tian C, Teoh D, et al. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116(3):307–11. doi:10.1016/j.ygyno.2009.10.074. CrossRefPubMed Chan JK, Tian C, Teoh D, et al. Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116(3):307–11. doi:10.1016/j.ygyno.2009.10.074. CrossRefPubMed
13.
Zurück zum Zitat McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1–6. CrossRefPubMed McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1–6. CrossRefPubMed
14.
Zurück zum Zitat Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194–200. CrossRefPubMed Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194–200. CrossRefPubMed
15.
Zurück zum Zitat Pignata S, Scambia G, Ferrandina G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegyleted liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 randomized phase III trial. J Clin Oncol. 2011;29(27):3628–35. doi:10.1200/JCO.2010.33.8566. CrossRefPubMed Pignata S, Scambia G, Ferrandina G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegyleted liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 randomized phase III trial. J Clin Oncol. 2011;29(27):3628–35. doi:10.1200/JCO.2010.33.8566. CrossRefPubMed
16.
Zurück zum Zitat Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regiments in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27(9):1419–25. doi:10.1200/JCO.2008.19.1684. CrossRefPubMedCentralPubMed Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regiments in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27(9):1419–25. doi:10.1200/JCO.2008.19.1684. CrossRefPubMedCentralPubMed
17.
Zurück zum Zitat Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial. Lancet. 2009;374(9698):1331–8. doi:10.1016/S0140–6736(09)61157–0. CrossRefPubMed Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial. Lancet. 2009;374(9698):1331–8. doi:10.1016/S0140–6736(09)61157–0. CrossRefPubMed
18.
Zurück zum Zitat Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83. CrossRefPubMed Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83. CrossRefPubMed
19.
Zurück zum Zitat Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96. doi:10.1056/NEJMoa1103799. CrossRefPubMed Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96. doi:10.1056/NEJMoa1103799. CrossRefPubMed
20.
Zurück zum Zitat Kim A, Ueda Y, Naka T, et al. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res. 2012;31:14. doi:10.1186/1756–9966-31–14. CrossRefPubMedCentralPubMed Kim A, Ueda Y, Naka T, et al. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res. 2012;31:14. doi:10.1186/1756–9966-31–14. CrossRefPubMedCentralPubMed
21.
Zurück zum Zitat Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14(5):195–208. CrossRefPubMedCentralPubMed Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14(5):195–208. CrossRefPubMedCentralPubMed
22.
Zurück zum Zitat Palmar MK, Ledermann JA, Columbo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.3 trial. Lancet. 2003;361(9375):2099–106. CrossRef Palmar MK, Ledermann JA, Columbo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.3 trial. Lancet. 2003;361(9375):2099–106. CrossRef
23.
Zurück zum Zitat Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699–707. CrossRefPubMed Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699–707. CrossRefPubMed
24.
Zurück zum Zitat Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28(20):3323–9. doi:10.1200/JCO.2009.25.7519.25. CrossRefPubMed Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28(20):3323–9. doi:10.1200/JCO.2009.25.7519.25. CrossRefPubMed
25.
Zurück zum Zitat Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomised study od recurrent and refractory ovarian cancer. Gynecol Oncol. 2004;95(1):1–8. CrossRefPubMed Gordon AN, Tonda M, Sun S, et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomised study od recurrent and refractory ovarian cancer. Gynecol Oncol. 2004;95(1):1–8. CrossRefPubMed
26.
Zurück zum Zitat Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26(6):890–6. doi:10.1200/JCO.2007.13.6606. CrossRefPubMed Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26(6):890–6. doi:10.1200/JCO.2007.13.6606. CrossRefPubMed
27.
Zurück zum Zitat Sehouli J, Stengel D, Harter P, et al. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer study group. J Clin Oncol. 2011;29(2):242–8. doi:10.1200/JCO.2009.27.8911. CrossRefPubMed Sehouli J, Stengel D, Harter P, et al. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer study group. J Clin Oncol. 2011;29(2):242–8. doi:10.1200/JCO.2009.27.8911. CrossRefPubMed
28.
Zurück zum Zitat Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–8. doi:10.1200/JCO.2013.51.4489. CrossRefPubMed Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–8. doi:10.1200/JCO.2013.51.4489. CrossRefPubMed
29.
Zurück zum Zitat Greer BE, Bundy BN, Ozols RF, et al. Implication of second-look laparotomy in the context of optimally resected stage II ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. Gynecol Oncol. 2005;99(1):71–9. CrossRefPubMed Greer BE, Bundy BN, Ozols RF, et al. Implication of second-look laparotomy in the context of optimally resected stage II ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group study. Gynecol Oncol. 2005;99(1):71–9. CrossRefPubMed
30.
31.
Zurück zum Zitat Santillan A, Gary R, Zuhurak ML, et al. Risk of epithelial ovarian cancer recurrence in patient with rising serum CA-125 levels within the normal range. J Clin Oncol. 2005;23(36);9338–43. CrossRefPubMed Santillan A, Gary R, Zuhurak ML, et al. Risk of epithelial ovarian cancer recurrence in patient with rising serum CA-125 levels within the normal range. J Clin Oncol. 2005;23(36);9338–43. CrossRefPubMed
32.
Zurück zum Zitat Piovano E, Attamente L, Macchi C, et al. The role of HE4 in ovarian cancer follow-up: a review. Int J Gynecol Cancer. 2014;24(8):1359–65. doi:10.1097/IGC.0000000000000218. CrossRefPubMed Piovano E, Attamente L, Macchi C, et al. The role of HE4 in ovarian cancer follow-up: a review. Int J Gynecol Cancer. 2014;24(8):1359–65. doi:10.1097/IGC.0000000000000218. CrossRefPubMed
33.
Zurück zum Zitat Gadducci A, Fuso L, Cosio S, et al. Are surveillance procedures of clinical benefit for patients treated for ovarian cancer? A retrospective Italian multicentric study. Int J Gynecol Cancer. 2009;19(3):367–74. doi:10.1111/IGC.0b013e3181a1cc02. CrossRefPubMed Gadducci A, Fuso L, Cosio S, et al. Are surveillance procedures of clinical benefit for patients treated for ovarian cancer? A retrospective Italian multicentric study. Int J Gynecol Cancer. 2009;19(3):367–74. doi:10.1111/IGC.0b013e3181a1cc02. CrossRefPubMed
34.
Zurück zum Zitat Rustin GJ, van der Burg ME, Griffin C. Early versus delayed treatment of relapsed ovarian cancer (MRC ov05/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155–63. doi:10.1016/S0140-6736(10)61268-8. CrossRefPubMed Rustin GJ, van der Burg ME, Griffin C. Early versus delayed treatment of relapsed ovarian cancer (MRC ov05/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155–63. doi:10.1016/S0140-6736(10)61268-8. CrossRefPubMed
35.
Zurück zum Zitat Rustin GJ. Follow-up with CA 125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed. Ann Oncol. 2011;22(8):viii45–8. doi:10.1093/annonc/mdr471. Rustin GJ. Follow-up with CA 125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed. Ann Oncol. 2011;22(8):viii45–8. doi:10.1093/annonc/mdr471.
36.
Zurück zum Zitat Wang F, Ye Y, Xu X, et al. CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreductive surgery. J Ovarian Res. 2013;6(1):14. doi:10.1186/1757–2215-6–14. CrossRefPubMedCentralPubMed Wang F, Ye Y, Xu X, et al. CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreductive surgery. J Ovarian Res. 2013;6(1):14. doi:10.1186/1757–2215-6–14. CrossRefPubMedCentralPubMed
37.
Zurück zum Zitat Xu X, Chen X, Dai Z, et al. Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer. J Exp Clin Cancer Res. 2013;32:61. doi:10.1186/1756-9966-32-61. CrossRefPubMedCentralPubMed Xu X, Chen X, Dai Z, et al. Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer. J Exp Clin Cancer Res. 2013;32:61. doi:10.1186/1756-9966-32-61. CrossRefPubMedCentralPubMed
38.
Zurück zum Zitat Tanner EJ, Chi DS, Eisenhauer EL, et al. Surveillance for detection of recurrent ovarian cancer: survival impact or lead-time bias? Gynecol Oncol. 2010;117(2):336–40. doi:10.1016/j.ygyno.2010.01.014. CrossRefPubMed Tanner EJ, Chi DS, Eisenhauer EL, et al. Surveillance for detection of recurrent ovarian cancer: survival impact or lead-time bias? Gynecol Oncol. 2010;117(2):336–40. doi:10.1016/j.ygyno.2010.01.014. CrossRefPubMed
40.
Zurück zum Zitat Fehm T, Heller F, Krämer S, et al. Evaluation of CA 125, physical and radiological findings in follow-up of ovarian cancer patients. Anticancer Res. 2005;25(3 A):1551–4. PubMed Fehm T, Heller F, Krämer S, et al. Evaluation of CA 125, physical and radiological findings in follow-up of ovarian cancer patients. Anticancer Res. 2005;25(3 A):1551–4. PubMed
41.
Zurück zum Zitat Bhosale P, Peungjesada S, Wei W, et al Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA 125 levels. Int J Gynecol Cancer. 2010;20(6):936–44. doi:10.1111/IGC.0b013e3181e82a7f. CrossRefPubMed Bhosale P, Peungjesada S, Wei W, et al Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA 125 levels. Int J Gynecol Cancer. 2010;20(6):936–44. doi:10.1111/IGC.0b013e3181e82a7f. CrossRefPubMed
42.
Zurück zum Zitat Risum S, Hogdall C, Markova E, et al. Influence of 2-(18 F)fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery. Int J Gynecol Cancer. 2009;19(4):600–4. doi:10.1111/IGL.0b013e3181e3cc94. CrossRefPubMed Risum S, Hogdall C, Markova E, et al. Influence of 2-(18 F)fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography on recurrent ovarian cancer diagnosis and on selection of patients for secondary cytoreductive surgery. Int J Gynecol Cancer. 2009;19(4):600–4. doi:10.1111/IGL.0b013e3181e3cc94. CrossRefPubMed
43.
Zurück zum Zitat Fulham MJ, Carter J, Baldey A, et al. The impact of PET-CT scan in suspected recurrent ovarian cancer: a prospective multicentre study as part of the Australian PET Date Collection Project. Gynecol Oncol. 2009;112(2):462–8. doi:10.1016/j.gyno.2008.08.027. CrossRefPubMed Fulham MJ, Carter J, Baldey A, et al. The impact of PET-CT scan in suspected recurrent ovarian cancer: a prospective multicentre study as part of the Australian PET Date Collection Project. Gynecol Oncol. 2009;112(2):462–8. doi:10.1016/j.gyno.2008.08.027. CrossRefPubMed
44.
Zurück zum Zitat Gu P, Pan LL, Wu SQ, et al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma. A systematic review and meta-analysis. Eur J Radiol. 2009;71(1):164–74. doi:10.1016/j.ejrad.2008.02.019. CrossRefPubMed Gu P, Pan LL, Wu SQ, et al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma. A systematic review and meta-analysis. Eur J Radiol. 2009;71(1):164–74. doi:10.1016/j.ejrad.2008.02.019. CrossRefPubMed
45.
Zurück zum Zitat Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines. Ann Oncol. 2013;24 (Suppl 6):vi24–32. PubMed Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines. Ann Oncol. 2013;24 (Suppl 6):vi24–32. PubMed
46.
Zurück zum Zitat Matkovic´ V, Haller H, Vrdoljak E, et al. [Clinical recommendations for diagnosing, treatment and monitoring of patients with ovarian cancer—Croatian Oncology Society and Croatian Society for Gynecology and Obstetrics as Croatian Medical Association units and Croatian Society of Gynecological Oncology]. Lijec Vjesn. 2013;135(9–10):235–41. PubMed Matkovic´ V, Haller H, Vrdoljak E, et al. [Clinical recommendations for diagnosing, treatment and monitoring of patients with ovarian cancer—Croatian Oncology Society and Croatian Society for Gynecology and Obstetrics as Croatian Medical Association units and Croatian Society of Gynecological Oncology]. Lijec Vjesn. 2013;135(9–10):235–41. PubMed
Metadaten
Titel
Optimal follow-up of ovarian cancer patients
verfasst von
MD, PhD Eduard Vrdoljak
MD Branka Petrić Miše
MD, PhD Tihana Boraska Jelavić
MD, PhD Snježana Tomić
MD, PhD Dinka Šundov
MD Ante Strikić
Publikationsdatum
01.04.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0188-y

Weitere Artikel der Ausgabe 1/2015

memo - Magazine of European Medical Oncology 1/2015 Zur Ausgabe